Dermatology biotech Timber Pharmaceuticals’ Phase 3 trial investigating its treatment in a rare inherited skin disorder missed all primary and secondary endpoints, the company announced …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
What You Should Know: – Bluesight, a provider of medication intelligence solutions, released its 2024 Diversion Trends Report, offering valuable insights for healthcare providers to
Researchers explore the potential utility of ginger essential oil in preventing NASH.
You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight